Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 29, 2009 (13 weeks)
Business Overview: Illumina is a leading developer and manufacturer of integrated systems for large-scale genetic analysis, serving sequencing, genotyping, and gene expression markets. The company operates primarily as a single segment, with limited activity in its emerging Diagnostics Business Unit.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenue | $165,757 | $121,861 |
| Net Income | $18,811 | $10,743 |
| Diluted EPS | $0.14 | $0.08 |
| Operating Cash Flow | $50,748 | $(26,755) |
| Cash & Equivalents (End of Period) | $351,146 | $118,614 |
| Total Investments | $377,344 | $368,951 |
| Current Portion of Long-Term Debt | $274,791 | $276,889 |
Margins: Gross margin (excluding amortization) improved to approximately 68% of revenue compared to 65% in the prior year. Operating margin increased to 21% from 16%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 36% year-over-year, driven by a 41% increase in product revenue. Product revenue growth was fueled by strong demand for Infinium BeadChips (consumables) and sequencing systems.
- Profitability: Net income increased 75% to $18.8 million. Operating income rose to $34.5 million from $19.0 million.
- Expense Increases:
- R&D: Increased 59% to $32.7 million due to personnel costs, lab expenses, and licensing agreements.
- SG&A: Increased 27% to $42.8 million, primarily due to sales force expansion and stock-based compensation.
- Interest Expense: Net interest expense increased significantly (512%) to $5.2 million, largely due to the retroactive adoption of FSP APB 14-1 regarding convertible debt accounting.
- Cash Flow: Operating cash flow turned positive at $50.7 million, a significant improvement from a $26.8 million outflow in the prior year, driven by net income and working capital management.
Guidance, Outlook, and Risks
- Outlook: Management expects current cash and operating income to fund operations for at least the next 12 months. Future capital needs depend on R&D progress, market developments, and potential acquisitions.
- Convertible Notes: The company's $400 million Convertible Senior Notes were convertible during the period April 1, 2009, through June 30, 2009. A $10 million conversion occurred in late 2008, settled in February 2009.
- Auction Rate Securities: The company holds $55.9 million in illiquid auction rate securities. A settlement with UBS allows the company to sell these at par between June 2010 and July 2012. The fair value of these securities and the associated put option are subject to volatility.
- Risks: Key risks include the uncertainty of litigation outcomes, the ability to raise capital if needed, price competition, and the realization of deferred tax assets (subject to valuation allowances).
- Accounting Changes: The adoption of FSP APB 14-1 required separating the liability and equity components of convertible debt, increasing reported interest expense and reducing net income compared to pre-adoption figures.
- Revenue Quality: Verify the sustainability of the 41% product revenue growth, specifically the mix shift toward higher-priced Infinium HD BeadChips versus unit volume.
- Debt Conversion: Monitor the status of the Convertible Senior Notes and potential dilution if conversion triggers are met in the coming quarters.
- Liquidity of Investments: Assess the risk associated with the $55.9 million in auction rate securities and the reliance on the UBS settlement for liquidity.
- Expense Trajectory: Evaluate if the 59% increase in R&D and 27% increase in SG&A are sustainable relative to revenue growth rates.
- Stock-Based Compensation: Note the significant non-cash stock-based compensation expense ($14.9 million) and its impact on future cash burn if equity markets fluctuate.